JPRN-UMIN000003751Not yet recruitingPhase 2
A phase II feasibility trial of Gemcitabine Hydrochloride and Krestin combination therapy in pancreatic cancer after surgery. - A phase II feasibility trial of Gemcitabine Hydrochloride and Krestin combination therapy in pancreatic cancer after surgery.
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Kyoto University Hospital
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Active double cancer. 2)Patients with severe myelosuppression. 3)Patients who receiving radiation therapy to the chest. 4)Patients with severe infection. 5)Patients with pulmonary fibrosis or interstitial lung disease. 6)Pregnant patients. 7)Patients with insanity or psychological symptom.
Investigators
Similar Trials
Completed
Phase 2
A randomized controlled trial of gemcitabine hydrochloride plus S-1 combination (GS) therapy and gemcitabine hydrochloride (Gem) therapy alone for patients with pancreatic cancer who are 75 years or older.Pancreatic cancerJPRN-UMIN000025747ational Hospital Organization Shikoku Cancer Center100
Unknown
Phase 2
A Phase II multicenter trial of Gemcitabine in combination with R1415 (erlotinibhydrochloride) in patients with unresectable pancreatic cancer (locally advanced or metastatic)Pancreatic cancerJPRN-jRCT2080220332Chugai Pharmaceutical Co., Ltd.
Active, not recruiting
Not Applicable
Phase II trial of the addition of gemcitabine to 131I-MIBG therapy in paediatric patients with relapsed or progressive neuroblastomarelapsed or progressive neuroblastoma in pediatric patients of 1 to 18 yearsEUCTR2007-007974-45-DEAMC47
Completed
Phase 2
Phase II trial of the combination of gemcitabine and 131I-MIBG therapy in paediatric patients with relapsed or progressive neuroblastomaNL-OMON39557Academisch Medisch Centrum16
Active, not recruiting
Not Applicable
A phase II study of the combination of gemcitabine with 131I-MIBG therapy for children with neuroblastoma without other treatment options.relapsed or progressive neuroblastoma in pediatric patients of 1 to 18 yearsEUCTR2007-007974-45-NLAMC47